Stockscreener 앱 받기
6.24
0.16%
-0.010
시간 외 거래:
6.25
0.010
+0.16%
전일 마감가:
$6.25
열려 있는:
$6.216
하루 거래량:
44,429
Relative Volume:
0.63
시가총액:
$69.77M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-2.95%
1개월 성능:
-18.96%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.17
$6.42
1주일 범위
$6.11
$6.68
52주 변동 폭
$6.11
$17.96
Imagenebio Inc Stock (IMA) Company Profile
명칭
Imagenebio Inc
전화
857-343-8292
주소
12526 HIGH BLUFF DRIVE, SAN DIEGO
IMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
6.24 | 69.89M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 재개 | Wedbush | Underperform |
| 2025-10-24 | 개시 | Leerink Partners | Outperform |
Imagenebio Inc 주식(IMA)의 최신 뉴스
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of “Hold” by Brokerages - Defense World
ImageneBio Extends Agreement with Miragene Inc. - MSN
ImageneBio (IMA) Stock Analysis Report | Financials & Insights - Benzinga
ImageneBio, Inc. (IMA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ImageneBio, Inc. (IMA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Wedbush Comments on ImageneBio's Q4 Earnings (NASDAQ:IMA) - MarketBeat
ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World
IMA interactive stock chart | ImageneBio, Inc. stock - Yahoo Finance Australia
Price performance - Yahoo Finance Australia
ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World
ImageneBio assumed at Underperform from Neutral at Wedbush - MSN
Sell Recommendation for ImageneBio Due to Strategic Risks and Financial Challenges - TipRanks
Wedbush assumes coverage of ImageneBio stock with Underperform rating By Investing.com - Investing.com South Africa
ImageneBio (IMA) Receives Underperform Rating from Wedbush | IMA Stock News - GuruFocus
Wedbush assumes coverage of ImageneBio stock with Underperform rating - Investing.com India
Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target - marketscreener.com
ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year - MSN
ImageneBio Highlights IMG-007 in Corporate Update - TipRanks
ImageneBio, Inc Updates Corporate Presentation for Q4 2025 - TradingView
FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs - Defense World
William Blair Estimates ImageneBio FY2025 Earnings - Defense World
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation - Yahoo Finance
ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to “Strong Sell” - Defense World
[424B3] ImageneBio, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
ImageneBio Reports Third Quarter 2025 Financial Results - TradingView
ImageneBio, Inc. SEC 10-Q Report - TradingView
ImageneBio Reports Third Quarter 2025 Financial Results and - GlobeNewswire
ImageneBio Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - The Manila Times
ImageneBio Expands Board, Appoints New Audit Chair - TipRanks
ImageneBio, Inc. Appoints Joseph P. Slattery to the Board, Effective November 1, 2025, and as Chair of the Audit Committee of the Board, Effective November 18, 2025 - MarketScreener
ImageneBio initiated with an Outperform at Leerink - MSN
ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update - Defense World
Miragene Inc. Announces Extension of Key Service Agreement - MarketScreener
Imagenebio Inc elects not to renew agreement with MirageneSEC filing - MarketScreener
ImageneBio IncOn Oct 23, Elects Not To Renew Agreement With MirageneSEC Filing - TradingView
Imagenebio IncExtends Term for Miragene Se - 富途牛牛
Leerink Partners initiates Imagene Bio stock with Outperform rating By Investing.com - Investing.com South Africa
Leerink Partners initiates Imagene Bio stock with Outperform rating - Investing.com India
IMA Analyst Forecasts - Quiver Quantitative
Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target - MarketScreener
This Albemarle Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Leerink Partners Initiates Coverage on ImageneBio (IMA) with Out - GuruFocus
ImageneBio’s IMG-007: A Promising Blockbuster in Atopic Dermatitis with Strategic Leadership and Competitive Edge - TipRanks
Weiss Ratings Initiates Coverage on ImageneBio (NASDAQ:IMA) - Defense World
ImageneBio, Inc.Common Stock (Nasdaq:IMA) Stock Quote - FinancialContent
ImageneBio appoints CEO Kristin Yarema as interim principal financial officer By Investing.com - Investing.com Nigeria
ImageneBio, Inc. Appoints Kristin Yarema as Interim Principal Financial Officer, Effective October 21, 2025 - MarketScreener
Imagenebio Inc (IMA) 재무 분석
Imagenebio Inc (IMA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):